Aqilion publishes Annual Report for 2024

AQILION AB (publ) hereby announces that the Swedish version of the 2024 Annual Report has been published.

The Annual Report, which is attached in Swedish, can also be downloaded from the company’s website. An English translation of the Annual Report will be available on the website no later than the week commencing May 19, 2025.

For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Aqilion

Aqilion is a biotechnology company focused on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immunological reactions such as autoimmune diseases.

We identify innovative ideas that have the potential to become new drugs and refine them into commercially interesting projects. The ideas we choose are based on a solid scientific foundation where we can clearly understand the underlying biology, clinical relevance and patient benefit with reasonable assumptions.

The company is primarily active in the early phases of drug development, from the idea stage to proof-of-concept in clinical studies. Aqilion runs its development programs in a partially virtual organization in close collaboration with selected partners with special cutting-edge knowledge in drug development.

AQILION AB (publ) is a Swedish public limited liability company headquartered in Helsingborg, Sweden. www.aqilion.com